Morgan Stanley Galera Therapeutics, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.14 - $0.27 $0 - $0	-3 Reduced 0.11%	2,831 $0
Q4 2023 Aug 16, 2024	BUY	$0.09 - $0.27 $254 - $764	2,831 New	2,831 $0
Q3 2023 Nov 15, 2023	SELL	$0.17 - $3.0 $597 - $10,536	-3,512 Reduced 55.34%	2,834 $0
Q2 2023 Aug 14, 2023	SELL	$2.5 - $3.42 $126,972 - $173,698	-50,789 Reduced 88.89%	6,346 $19,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $83,981 - $152,073	56,744 Added 14512.53%	57,135 $146,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $925 - $1,229	-691 Reduced 63.86%	391 $0
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $3,478 - $6,352	-3,025 Reduced 73.65%	1,082 $2,000
Q2 2022 Oct 27, 2022	SELL	$1.24 - $2.39 $1,786 - $3,443	-1,441 Reduced 25.97%	4,107 $6,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $1,786 - $3,443	-1,441 Reduced 25.97%	4,107 $6,000
Q1 2022 Oct 27, 2022	BUY	$2.01 - $4.19 $2,896 - $6,037	1,441 Added 35.09%	5,548 $13,000
Q1 2022 May 13, 2022	SELL	$2.01 - $4.19 $371,785 - $775,015	-184,968 Reduced 97.09%	5,548 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $234,833 - $1.53 Million	184,908 Added 3297.22%	190,516 $874,000
Q3 2021 Nov 15, 2021	BUY	$7.04 - $10.49 $39,480 - $58,827	5,608 New	5,608 $45,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $2.15M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.